Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Mather Group LLC.

Mather Group LLC. lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 98.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,588 shares of the biopharmaceutical company's stock after buying an additional 6,731 shares during the quarter. Mather Group LLC.'s holdings in Gilead Sciences were worth $1,523,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Alta Advisers Ltd boosted its position in Gilead Sciences by 57.3% during the first quarter. Alta Advisers Ltd now owns 6,592 shares of the biopharmaceutical company's stock worth $739,000 after purchasing an additional 2,400 shares in the last quarter. Lodestar Private Asset Management LLC boosted its position in Gilead Sciences by 3.6% during the first quarter. Lodestar Private Asset Management LLC now owns 2,840 shares of the biopharmaceutical company's stock worth $318,000 after purchasing an additional 100 shares in the last quarter. Deseret Mutual Benefit Administrators boosted its position in Gilead Sciences by 4.6% during the first quarter. Deseret Mutual Benefit Administrators now owns 17,848 shares of the biopharmaceutical company's stock worth $2,000,000 after purchasing an additional 784 shares in the last quarter. Smallwood Wealth Investment Management LLC purchased a new stake in Gilead Sciences during the first quarter worth $25,000. Finally, CHURCHILL MANAGEMENT Corp purchased a new stake in Gilead Sciences during the first quarter worth $4,855,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Trading Down 0.2%

NASDAQ:GILD traded down $0.24 during mid-day trading on Friday, reaching $111.28. The company's stock had a trading volume of 4,039,811 shares, compared to its average volume of 7,692,289. The company's fifty day simple moving average is $107.02 and its two-hundred day simple moving average is $103.93. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23. Gilead Sciences, Inc. has a twelve month low of $66.01 and a twelve month high of $119.96. The stock has a market cap of $138.42 billion, a P/E ratio of 23.43, a P/E/G ratio of 0.72 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The company had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The company's quarterly revenue was down .3% compared to the same quarter last year. During the same period last year, the business posted ($1.32) EPS. On average, equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Stockholders of record on Friday, June 13th were issued a $0.79 dividend. The ex-dividend date of this dividend was Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.84%. Gilead Sciences's dividend payout ratio (DPR) is 66.53%.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $110.17, for a total value of $275,425.00. Following the transaction, the chief financial officer directly owned 165,110 shares in the company, valued at $18,190,168.70. This trade represents a 1.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction dated Friday, May 30th. The stock was sold at an average price of $110.42, for a total value of $1,104,200.00. Following the completion of the transaction, the chief executive officer owned 620,268 shares in the company, valued at approximately $68,489,992.56. This trade represents a 1.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 58,500 shares of company stock worth $6,340,745 in the last three months. 0.27% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms have commented on GILD. JPMorgan Chase & Co. boosted their target price on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Morgan Stanley boosted their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Cantor Fitzgerald initiated coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price objective on the stock. Finally, Oppenheimer reduced their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Nine analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of "Moderate Buy" and a consensus target price of $110.55.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.